Endothelial PAS domain-containing protein 1 (EPAS1), also HIF2α, is an alpha subunit of hypoxia-inducible transcription factor (HIF), which mediates cellular and systemic response to hypoxia. EPAS1 has an important role in the transcription of many hypoxia-responsive genes, however, it has been less researched than HIF1α. The aim of this study was to integrate an increasing number of data on EPAS1 into a map of diverse OMICs elements. Publications, databases, and bioinformatics tools were examined, including Ensembl, MethPrimer, STRING, miRTarBase, COSMIC, and LOVD. The EPAS1 expression, stability, and activity are tightly regulated on several OMICs levels to maintain complex oxygen homeostasis. In the integrative EPAS1 map we included: 31 promoter-binding proteins, 13 interacting miRNAs and one lncRNA, and 16 post-translational modifications regulating EPAS1 protein abundance. EPAS1 has been associated with various cancer types and other diseases. The development of neuroendocrine tumors and erythrocytosis was shown to be associated with 11 somatic and 20 germline variants. The integrative map also includes 12 EPAS1 target genes and 27 interacting proteins. The study introduced the first integrative map of diverse genomics, transcriptomics, proteomics, regulomics, and interactomics data associated with EPAS1, to enable a better understanding of EPAS1 activity and regulation and support future research.
Background: Erythrocytosis is a condition with an excessive number of erythrocytes, accompanied by an elevated haemoglobin and/or haematocrit value. Congenital erythrocytosis has a diverse genetic background with several genes involved in erythropoiesis. In clinical practice, nine genes are usually examined, but in approximately 70% of patients, no causative mutation can be identified. In this study, we screened 39 genes, aiming to identify potential disease‐driving variants in the family with erythrocytosis of unknown cause.Patients and Methods: Two affected family members with elevated haemoglobin and/or haematocrit and negative for acquired causes and one healthy relative from the same family were selected for molecular‐genetic analysis of 24 erythrocytosis and 15 hereditary haemochromatosis‐associated genes with targeted NGS. The identified variants were further analysed for pathogenicity using various bioinformatic tools and review of the literature.Results: Of the 12 identified variants, two heterozygous variants, the missense variant c.471G>C (NM_022051.2) (p.(Gln157His)) in the EGLN1 gene and the intron variant c.2572‐13A>G (NM_004972.3) in the JAK2 gene, were classified as low‐frequency variants in European population. None of the two variants were present in a healthy family member. Variant c.2572‐13A>G has potential impact on splicing by one prediction tool.Conclusion: For the first time, we included 39 genes in the erythrocytosis clinical panel and identified two potential disease‐driving variants in the Slovene family studied. Based on the reported functional in vitro studies combined with our bioinformatics analysis, we suggest further functional analysis of variant in the JAK2 gene and evaluation of a cumulative effect of both variants.
Erythrocytosis, a disorder with increased erythrocyte production, has a heterogeneous aetiology, including rare congenital types linked to dysregulation of the oxygen-sensing pathway. Variants in the EGLN1 gene, encoding the prolyl hydroxylase that regulates hypoxia-inducible factor (HIF) stability, are associated with familial erythrocytosis type 3 (ECYT3). In patients with idiopathic erythrocytosis we previously identified two novel EGLN1 variants, c.1072C>T (p.(Pro358Ser)) and c.1124A>G (p.(Glu375Gly)), classified as variants of uncertain significance. Herein, we performed in silico and in vitro analyses to assess their structural and functional effects, using the known pathogenic variant p.(His374Arg) as a positive control. AlphaFold3 predictions revealed minimal conformational changes in the protein core for all variants, while stability predictions suggested reduced protein stability. Functional assays in HEK293 cells demonstrated significantly decreased protein levels and stability for p.(Pro358Ser) and p.(Glu375Gly), comparable to p.(His374Arg). However, luciferase reporter assays showed that, unlike p.(His374Arg), the novel variants did not substantially impair EGLN1 enzymatic activity or activate HIF signalling. Our results suggest that the novel variants may contribute to erythrocytosis through destabilization of EGLN1, supporting further studies to elucidate their precise impact on hypoxia regulation. This study highlights the complexity of studying EGLN1 variants and the importance of functional evaluation for clinical interpretation.
Erythrocytosis is a condition of increased red cell mass and has a very heterogeneous etiology. Patients may be asymptomatic or have symptoms and signs of increased blood viscosity. A diagnostic algorithm is applied to confirm the precise etiology necessary for appropriate treatment. In the first step, we have to confirm absolute erythrocytosis with hemoglobin (Hb) > 185 g/L and/or hematocrit (Ht) > 0.52 for men and Hb > 165 g/L and/or Ht > 0.48 for women. In the second step, we exclude polycythaemia vera and also search for secondary acquired causes such as lung-, heart- and kidney diseases and tumours with exogenous erythropoietin secretion. It is worth mentioning that according to the WHO guidelines, the diagnosis of polycythaemia vera in patients with an appropriate clinical picture is indicated at lower values, more precisely, Hb > 165 g/L or Ht > 0.49 for men and Hb > 160 g/L or Ht > 0.48 for women. In the third step, we refer patients without a known cause of erythrocytosis for genetic testing to identify congenital erythrocytosis. People in whom we have excluded polycythaemia vera, secondary acquired and congenital erythrocytosis, have idiopathic erythrocytosis. Treatment depends on the cause of the erythrocytosis. Most commonly, it includes acetylsalicylic acid and venipunctures.